Plain-English translation of NCT06364930 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This is a study testing whether a medication called dapagliflozin can help protect the liver in people who have both chronic hepatitis B and type 2 diabetes. Dapagliflozin is already used to treat diabetes and has shown promise in reducing liver damage and inflammation in other conditions. Researchers want to see if it can prevent serious liver complications in patients with hepatitis B.
People with chronic hepatitis B face a serious risk of liver disease that can lead to scarring, cancer, and life-threatening complications. This medication has been shown to reduce inflammation and improve liver health in other conditions, so doctors want to test whether it can offer similar protection for hepatitis B patients who also have diabetes.
You likely qualify if…
You likely don't qualify if…
You will take either the study medication or a placebo (inactive pill) once daily for 60 months (5 years). Half of participants will receive dapagliflozin 10 mg, and half will receive a placebo—neither you nor the research team will know which you are taking. During the study, you will have regular clinic visits with blood tests and imaging scans to monitor your liver health, kidney function, and diabetes control.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Hong Kong